

RECORDATI: PUBLICATION OF THE SLATES OF CANDIDATES FOR THE APPOINTMENT OF THE STATUTORY AUDITORS OF THE COMPANY

Milan, 31st March 2023 – Pursuant to art. 144-octies, paragraph 1 of Consob's Regulation 11971/1999 ("Issuers' Regulations") and with reference to the Ordinary General Meeting of the Shareholders to be held on 21st April 2023 in a single call, RECORDATI S.p.A. informs that the following slates for the appointment of the Statutory Auditors are available to the public on the "1info" storage mechanism (www.1info.it), at the Company's corporate seat and on its website (www.recordati.it - section Investors - Shareholders Meetings):

- the slate filed by the majority shareholder, Rossini S. à r.l., which owns 51.82% of RECORDATI S.p.A.'s share capital (Slate No. 1);
- the slate filed by a group of asset management companies and institutional investors which collectively own 0.51686% of RECORDATI S.p.A.'s share capital (Slate No. 2).

Please note that the above-mentioned slates are available jointly with the relevant documentation requested by law and by the Company's By-laws.

Recordati, (Reuters RECI.MI, Bloomberg REC IM), established in 1926, is an international pharmaceutical group listed on the Italian Stock Exchange (ISIN IT 0003828271), with a total staff of more than 4,300, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in Europe, Russia and other countries of the CIS, Ukraine, Turkey, North Africa, the United States, Canada, Mexico, some South American countries, Japan, Australia and New Zealand, China and South Korea. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under licence, from a number of therapeutic areas, including a global specialised business, dedicated to rare diseases. Recordati is a partner of choice for new product licences for its territories. Recordati is committed to the research and development of new specialties with a focus on treatments for rare diseases. Consolidated revenue for 2022 was € 1,853.3 million, operating income was € 437.3 million and net income was € 312.3 million.

For further information:

Recordati website: www.recordati.com

Investor Relations

Federica De Medici

(39) 02 48787146

e-mail: investorelations@recordati.it e

Investor Relations

Lucia Abbatantuoni

(39) 02 48787213

e-mail: investorelations@recordati.it e

Ufficio stampa

Brunswick: Barbara Scalchi / Andrea Mormandi

(39) 02 9288 6200

e-mail: recordati@brunswickgroup.com

RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.A.

Registered Office

Via Matteo Civitali, 1

20148 Milano, Italy

Ph. (39) 02 487871

Fax (39) 02 40073747

www.recordati.com

Share Capital € 26.140.644,50 fully paid-up

Milano, Monza, Brianza and Lodi Comp. Reg. No. 00748210150

Tax Code/VAT No. 00748210150

Milano R.E.A. No. 401832

Company subject to the Management and Coordination Activity of Rossini Luxembourg S.à.r.l